we have witnessed a major evolution in thinking from the view that the heart and blood vessels are mechanical organs that respond to nerves and hormones to the recognition that the cardiovascular tissues are biologically active organs capable of synthesizing active molecules that participate in the regulation of cardiac and vascular function.2,3 Indeed, vascular biology research has demonstrated the existence and potential functions of growth factors, cytokines, adhesion molecules, and vasoactive substances. Abnormalities in expression and/or action of these local substances have been shown to be associated with vascular diseases such as atherosclerosis.4 Although evidence for the role of some of the autocrine/paracrine factors is sometimes circumstantial, the scientific community has enthusiastically supported with an open mind continued research to study further these new concepts in cardiovascular biology. As a consequence of this effort and commitment, the application of in vivo gene transfer, transgenic technology, and homologous recombination have now shown the importance of many of these factors in the pathophysiology of vascular disease.5-8
we have witnessed a major evolution in thinking from the view that the heart and blood vessels are mechanical organs that respond to nerves and hormones to the recognition that the cardiovascular tissues are biologically active organs capable of synthesizing active molecules that participate in the regulation of cardiac and vascular function.2,3 Indeed, vascular biology research has demonstrated the existence and potential functions of growth factors, cytokines, adhesion molecules, and vasoactive substances. Abnormalities in expression and/or action of these local substances have been shown to be associated with vascular diseases such as atherosclerosis. 4 Although evidence for the role of some of the autocrine/paracrine factors is sometimes circumstantial, the scientific community has enthusiastically supported with an open mind continued research to study further these new concepts in cardiovascular biology. As a consequence of this effort and commitment, the application of in vivo gene transfer, transgenic technology, and homologous recombination have now shown the importance of many of these factors in the pathophysiology of vascular disease.5-8 The Throughout the article, the authors confused renin, an enzyme, as being a "hormone." For the circulating RAS, angiotensin II is the hormone. Thus, one would not expect the enzyme renin to have a tissue receptor or to have direct cellular action as stated by the authors. For this reason, we believe it is most appropriate to focus more on local angiotensin production and action when one attempts to understand tissue angiotensin in the cardiovascular system. For example, although debate may exist as to the contribution of tissue renin, nonrenin enzymes, and ACE-like enzymes for Ang II production, there is unequivocal evidence for the existence of ACE in blood vessels and tissues and for the importance of this enzyme in converting Ang I to Ang II. Although the term tissue RAS was intended originally to embrace the general concept of tissue angiotensin production by one or multiple components of RAS at local sites, the considerable debate over tissue renin, nonrenin enzymes, etc, suggests that this term has very specific connotations to some investigators. To avoid losing the focus of the concept of tissue angiotensin synthesis, we believe that the broader concept of a functional tissue angiotensin system and its physiological and pathological implications is a more useful concept than tissue RAS. Studies to understand the regulation of tissue Ang II production, the contribution of ACE and possibly other enzymes, the possible differences among tissues (vascular versus parenchymal), and the function of local angiotensin (especially in humans) are important future directions of research in tissue angiotensin systems.
The paper of Lutterotti et al also stated that renin substrate and ACE are not rate limiting for angiotensin II Taken together, these data suggest that in addition to the circulating RAS, local angiotensin production is an important modulator of tissue function and structure. Although tissue RAS components may be either of local or circulating origin, these local compartments may generate Ang II with different enzyme-substrate concentrations and kinetics. Although circulating RAS is important for systemic cardiovascular regulation, in individual tissues the production of angiotensin can be altered by local activation of tissue ACE and/or other components, which may not result in a systemic blood pressure effect but can result in altered local function such as cardiac and vascular remodeling, atherosclerosis, and possibly restenosis. Accordingly, one must view the local angiotensin system in the context of local tissue function beyond blood pressure regulation. Therefore, the notion that local RAS in cardiovascular tissue is unimportant, based on the observation that the acute blood pressure responses to renin or ACE inhibitors or to nephrectomy parallel the levels of plasma renin, must be rejected.
Finally, the authors recommended a "redirection" of research efforts to renal renin. We believe that investigations of renal and tissue RAS are not mutually exclusive but rather highly complementary. The complexity and the dynamics of these systems must be defined further. Renal renin was described approximately 100 years ago.58 Tissue RAS is a recent concept, and much more research is necessary to define its origin, regulation, and function. A "redirection" to only renal renin research would represent a step backward. Rather, we should embrace new concepts, combine the strengths of molecular, cellular, and physiological research, and test objectively and definitively the significance of autocrine/paracrine angiotensin as well as other local mediators. Such research may lead to novel discoveries that result in paradigm shifts-the building the size of the neointima. To examine further the blocks of knowledge and science. 
